<DOC>
	<DOCNO>NCT02825160</DOCNO>
	<brief_summary>This study collect post-marketing information safety effectiveness Ventavis routine clinical practice patient PAH</brief_summary>
	<brief_title>Non-interventional , Postauthorization Safety Study Ventavis Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>This local , prospective , non-interventional , company sponsor , multi-center , single-cohort study include patient treat Ventavis PAH . A total 270 patient ( valid safety analysis ) plan enrol 5 year . Target population patient PAH diagnosis . This study perform all-patient investigation , therefore patient receive Ventavis treatment PAH need register . The treatment perform base product label Japan . The standard observation period last 12 month start Ventavis treatment . In addition , extension observation carry long Ventavis treatment continue 4 year . The standard observation point 3 month 1 5 year .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Patients diagnose PAH Patients decision initiate treatment Ventavis make per investigator 's routine treatment practice N/A</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Iloprost</keyword>
	<keyword>Ventavis</keyword>
	<keyword>Prostacycline analogue</keyword>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>Japan</keyword>
	<keyword>Post-marketing surveillance</keyword>
</DOC>